Group items tagged

Society for Neuroscience (SfN) 47th Annual Meeting is organized by Society for Neuroscience (SFN) and would be held during Nov 11 - 15, 2017 at Walter E. Washington Convention Center, Washington, Dis of Col, United States of America. CME Credits: * Symposia - SfN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. * Minisymposia - SfN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. * Basic-Translational-Clinical Roundtables - SfN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. * Albert and Ellen Grass Lecture - SfN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. * Presidential Special Lectures - SfN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits. * Special Lectures - SfN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits.

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.